Analysed PYXIS ONCOLOGY INC (PYXS:NASDAQ) News Sources
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026
17-04-2026
yahoo.com
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
14-05-2026
yahoo.com
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
13-08-2026
yahoo.com
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board
08-09-2026
yahoo.com
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
08-09-2026
yahoo.com
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
09-09-2026
yahoo.com
What is the current price of PYXIS ONCOLOGY INC (PYXS:NASDAQ)?
The current price of PYXIS ONCOLOGY INC (PYXS:NASDAQ) is $3.27.
PYXIS ONCOLOGY INC (PYXS:NASDAQ) absolute price change since previous trading day?
The absolute price change of PYXIS ONCOLOGY INC (PYXS:NASDAQ) since the previous trading day is $-0.11.
PYXIS ONCOLOGY INC (PYXS:NASDAQ) percentage price change since previous trading day?
The percentage price change of PYXIS ONCOLOGY INC (PYXS:NASDAQ) since the previous trading day is -3.2544%.
What is the most recent average sentiment score for PYXIS ONCOLOGY INC (PYXS:NASDAQ)?
The most recent average sentiment score for PYXIS ONCOLOGY INC (PYXS:NASDAQ) is 69 out of 100.
What is the most recent average sentiment for PYXIS ONCOLOGY INC (PYXS:NASDAQ)?
The most recent sentiment for PYXIS ONCOLOGY INC (PYXS:NASDAQ) is .
SEC-8K** Filing Available For PYXIS ONCOLOGY INC (PYXS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.